Systematic review of human papillomavirus vaccine coadministration

Vaccine

Volumn 32, Issue 23, 2014, Pages 2670-2674

  Noronha, Alinea S ^a   Markowitz, Lauri E ^a   Dunne, Eileen F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Coadministration; Concomitant; HPV vaccination; Immunogenicity; Safety

Indexed keywords

DIPHTHERIA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE;

ADOLESCENCE; DRUG SAFETY; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VACCINATION; WART VIRUS;

COADMINISTRATION; CONCOMITANT; HPV VACCINATION; IMMUNOGENICITY; SAFETY;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; PAPILLOMAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84899934554     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.037     Document Type: Review

References (19)

1. Centers for Disease Control and Prevention (CDC) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):626-629.
2. Centers for Disease Control and Prevention (CDC) FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59(20):630-632.
3. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 20(30 (Suppl. 5)):F123-F138.
4. Centers for Disease Control and Prevention (CDC) Recommended immunization schedules for persons aged 0 through 18 years - United States, 2012. MMWR Morb Mortal Wkly Rep 2012, 61(5):1-4.
5. Centers for Disease Control and Prevention (CDC) Quadrivalent human papillomavirus vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007, 56(2):12.
6. Wheeler C.M., Bautista O.M., Tomassini J.E., Nelson M., Sattler C.A., Barr E., et al. Safety and immunogenicity of coadministered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008, 26(5):686-696.
7. Vesikari T., Van Damme P., Lindblad N., Pfletschinger U., Radley D., Ryan D., et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010, 29(4):314-318.
8. Arguedas A., Soley C., Loaiza C., Rincon G., Guevara S., Perez A., et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010, 28(18):3171-3179.
9. Reisinger K.S., Block S.L., Collins-Ogle M., Marchant C., Catlett M., Radley D., et al. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010, 125(6):1142-1151.
10. Garcia-Sicilia J., Schwarz T.F., Carmona A., Peters K., Malkin J.E., Tran P.M., et al. HPV Vaccine Adolescent Study Investigators Network. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010, 46(2):142-151.
11. Wheeler C.M., Harvey B.M., Pichichero M.E., Simon M.W., Combs S.P., Blatter M.M., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J 2011, 30(12):e225-e234. 14.
12. Leroux-Roels G., Haelterman E., Maes C., Levy J., De Boever F., Licini L. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Clin Vaccine Immunol 2011, 18(9):1510-1518.
13. Schmeink C.E., Bekkers R.L., Josefsson A., Richardus J.H., Berndtsson Blom K., David M.P., et al. Coadministration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011, 29(49):9276-9283.
14. Pedersen C., Breindahl M., Aggarwal N., Berglund J., Oroszlán G., Silfverdal S.A. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health 2012, 50(1):38-46.
15. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
16. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
17. Gasparini R., Conversano M., Bona G., Gabutti G., Anemona A., Dull P.M., et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010, 17(4):537-544.
18. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16(20):1901-1906.
19. National Vaccine Advisory Meeting (NVAC). ; 2013 [accessed June 2013]. http://www.hhs.gov/nvpo/nvac/meetings/pastmeetings/2013/epidemiology_immunization_feb2013.pdf.